Tag Archive for: Sanofi

Neuraxpharm announces closing of acquisition of established products from Sanofi

Düsseldorf and Barcelona – February 1, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the closing of the previously announced acquisition of two established product portfolios for CNS disorders, pain and vascular diseases from Sanofi. Read more…

Sanofi offers to acquire Kiadis for €308 million

Congratulations to Kiadis Pharma on recently announcing that it is being acquired by Sanofi in a deal valued at approximately €308m ($359m), a 272% premium over last week’s closing price, one of the largest premiums in European biotech. After the discontinuation of its lead product candidate and subsequent reorganization in 2019, Kiadis started 2020 as an entirely new company […]